EMEA-002166-PIP01-17-M07 - paediatric investigation plan

lasmiditan

Key facts

• Invented name:
  Reyvow
• Active Substance:
  lasmiditan
• Therapeutic area:
  Neurology
• Decision number:
  P/0175/2023
• PIP number:
  EMEA-002166-PIP01-17-M07
• Pharmaceutical form(s):
  • Tablet
  • Orodispersible tablet
• Condition(s) / indication(s):
  Treatment of migraine
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  15/05/2023

Decision

P/0175/2023: EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (Rayvow), (EMEA-002166-PIP01-17-M07)

Reference Number: EMA/177631/2023